281 patents currently held
36 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
28
Ending by 2030
Dec 2026
Next term end
175
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2035 · High confidence
Also notable
Ends Jun 2034 · High confidence
Also notable
Ends Dec 2033 · High confidence
Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS
US 9,856,318
Cited by 74 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Plant with Altered Content of Steroidal Alkaloids
US 10,806,119
Cited by 27 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2034.
Molecular Sensor and Methods of Use Thereof
US 9,696,310
Cited by 29 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Formerly held, still cited
Notable
Ends Jul 2028 · High confidence
The most cited patent in this portfolio, cited by 167 later US patents, top 5% of utility patents granted in 2011 in our data. Protection runs to 2028.
now held by Brainsway, Ltd.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 6 fees due Dec 2 to 30, 2026 · next Dec 2
- 2 fees due Jan 2 to 23, 2027 · next Jan 2
- 5 fees due Feb 6 to 22, 2027 · next Feb 6
- 3 fees due Mar 5 to 19, 2027 · next Mar 5
- 10 fees due Apr 1 to 29, 2027 · next Apr 1
- 4 fees due May 3 to 19, 2027 · next May 3
- 10 fees due Jun 5 to 30, 2027 · next Jun 5
- 8 fees due Jul 7 to 30, 2027 · next Jul 7
- 10 fees due Aug 4 to 20, 2027 · next Aug 4
- 6 fees due Sep 5 to 22, 2027 · next Sep 5
- 9 fees due Oct 2 to 30, 2027 · next Oct 2
- 2 fees due Nov 7 to 14, 2027 · next Nov 7
Recent changes
- Oct 16Assignment recorded on 1 record: Globerson Levin, Anat and 2 others to Yeda Research and Development Co. Ltd. Recorded Oct 16, 2026, executed May 3, 2022. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76413, frame 244.
- 12 of the patents on this record were granted since Aug 18, 2026
- 6 terms have ended since Aug 18, 2026
What they patent
The 5 largest of its 175 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,388,954 | Stabilising Formulation for Immunoglobulin G Compositions in Liquid Form and in Lyophilised Form In force · High confidence | In force | High confidence | |
| US 7,897,840 | Salt Responsive Genes Useful for Generating Salt Resistant Transgenic Plants In force · High confidence | In force | High confidence | |
| US 10,258,651 | Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS In force · High confidence | In force | High confidence | |
| US 11,406,670 | Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS In force · High confidence | In force | High confidence | |
| US 10,689,415 | Conjugates of RGD Peptides and (BACTERIO)CHLOROPHYLL Photosensitizers In force · Medium confidence | In force | Medium confidence | |
| US 7,947,672 | Water-Soluble Anionic Bacteriochlorophyll Derivatives and Their Uses In force · Medium confidence | In force | Medium confidence | |
| US 8,067,008 | Peptide Inhibitors for Mediating Stress Responses In force · High confidence | In force | High confidence | |
| US 9,631,175 | Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS In force · High confidence | In force | High confidence | |
| US 11,326,147 | Redirected, Genetically-Engineered T Regulatory Cells and Their Use in Suppression of Autoimmune and Inflammatory Disease In force · High confidence | In force | High confidence | |
| US 8,486,653 | Antibodies and Pharmaceutical Compositions Containing Same Useful for Inhibiting Activity of Metalloproteins In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 281: 36 patents in force now held by others · 343 patents ended · 203 applications pending · 472 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.